GHRP-6
Also called Growth hormone-releasing peptide-6.
GHRP-6 has no FDA-approved product. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
An acute controlled experiment in 18 healthy men found that intravenous GHRP-6 stimulated growth hormone release compared with placebo. Prolactin and cortisol also rose at the highest studied exposure.
Limits: This small physiology study measured short-term hormone changes after monitored administration. It did not establish sustained muscle growth, fat loss, physical-function improvement, or longer life, and cannot establish a long-term subcutaneous schedule.
Regulatory status
United States
GHRP-6 has no FDA-approved human drug product. FDA has identified products containing it as unapproved drugs. Historical human hormone-response studies do not establish an approved indication, an effective chronic treatment schedule, or the safety of preparations sold for muscle gain or aging.